In vivo evaluation of safety and toxicity of a Lactobacillus jensenii producing modified cyanovirin-N in a rhesus macaque vaginal challenge model

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Brichacek, Beda ^a   Lagenaur, Laurel A ^a,b   Lee, Peter P ^b   Venzon, David ^a   Hamer, Dean H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Osel Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 13; LACTOBACILLUS JENSENII MODIFIED CYANOVIRIN N; MICROBICIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIUM CULTURE; BIOMEDICAL ENGINEERING; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOKINE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; LACTOBACILLUS JENSENII; MENSTRUAL CYCLE; MICROBIOME; NONHUMAN; PH MEASUREMENT; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VAGINA MUCOSA; VIRUS INHIBITION; VIRUS LOAD; VIRUS STRAIN;

ANIMALS; ANTI-INFECTIVE AGENTS, LOCAL; BACTERIAL PROTEINS; BIOLOGICAL MARKERS; CARRIER PROTEINS; COINFECTION; CYTOKINES; DISEASE MODELS, ANIMAL; DISEASE SUSCEPTIBILITY; FEMALE; HYDROGEN-ION CONCENTRATION; INFLAMMATION MEDIATORS; LACTOBACILLUS; MACACA MULATTA; MENSTRUAL CYCLE; MICROBIOTA; MUCOUS MEMBRANE; RISK FACTORS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VAGINA; VAGINITIS;

EID: 84893157111     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078817     Document Type: Article

References (47)

1. Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, et al. (2001) Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 357: 1149-1153.
2. Hladik F, Hope TJ (2009) HIV infection of the genital mucosa in women. Curr HIV/AIDS Rep 6: 20-28.
3. Abdool Karim Q, Sibeko S, Baxter C (2010) Preventing HIV infection in women: a global health imperative. Clin Infect Dis 50 Suppl 3: S122-129.
4. Hughes JP, Baeten JM, Lingappa JR, Magaret AS, Wald A, et al. (2012) Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples. J Infect Dis 205: 358-365.
5. Cohen MS (2004) HIV and sexually transmitted diseases: lethal synergy. Top HIV Med 12: 104-107.
6. Galvin SR, Cohen MS (2004) The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol 2: 33-42.
7. de Jong MA, Geijtenbeek TB (2009) Human immunodeficiency virus-1 acquisition in genital mucosa: Langerhans cells as key-players. J Intern Med 265: 18-28.
8. Mayer KH, Venkatesh KK (2011) Interactions of HIV, other sexually transmitted diseases, and genital tract inflammation facilitating local pathogen transmission and acquisition. Am J Reprod Immunol 65: 308-316.
9. Thurman AR, Doncel GF (2011) Innate immunity and inflammatory response to Trichomonas vaginalis and bacterial vaginosis: relationship to HIV acquisition. Am J Reprod Immunol 65: 89-98.
10. Hawes SE, Hillier SL, Benedetti J, Stevens CE, Koutsky LA, et al. (1996) Hydrogen peroxide-producing lactobacilli and acquisition of vaginal infections. J Infect Dis 174: 1058-1063.
11. Hillier SL (1998) The vaginal microbial ecosystem and resistance to HIV. AIDS Res Hum Retroviruses 14 Suppl 1: S17-21.
12. Taha TE, Hoover DR, Dallabetta GA, Kumwenda NI, Mtimavalye LA, et al. (1998) Bacterial vaginosis and disturbances of vaginal flora: association with increased acquisition of HIV. AIDS 12: 1699-1706.
13. Martin HL, Richardson BA, Nyange PM, Lavreys L, Hillier SL, et al. (1999) Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. J Infect Dis 180: 1863-1868.
14. Boskey ER, Cone RA, Whaley KJ, Moench TR (2001) Origins of vaginal acidity: high D/L lactate ratio is consistent with bacteria being the primary source. Hum Reprod 16: 1809-1813.
15. Atashili J, Poole C, Ndumbe PM, Adimora AA, Smith JS (2008) Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. Aids 22: 1493-1501.
16. Karim SS (2012) CAPRISA 004 TWO YEARS ON: WHAT WERE THE LESSONS, WHAT ARE THE IMPLICATIONS? Microbicides 2012. Sydney, Australia.
17. Roberts L, Passmore JA, Mlisana K, Williamson C, Little F, et al. (2012) Genital tract inflammation during early HIV-1 infection predicts higher plasma viral load set point in women. J Infect Dis 205: 194-203.
18. Hillier SL, Moench T, Shattock R, Black R, Reichelderfer P, et al. (2005) In vitro and in vivo: the story of nonoxynol 9. J Acquir Immune Defic Syndr 39: 1-8.
19. Van Damme L, Govinden R, Mirembe FM, Guedou F, Solomon S, et al. (2008) Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med 359: 463-472.
20. Mesquita PM, Cheshenko N, Wilson SS, Mhatre M, Guzman E, et al. (2009) Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety. J Infect Dis 200: 599-608.
21. Ravel J, Gajer P, Li F, Mauck CK, Koenig SS, et al. (2012) Twice-Daily Application of HIV Microbicides Alter the Vaginal Microbio. MBio 3.
22. Fichorova RN, Tucker LD, Anderson DJ (2001) The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. J Infect Dis 184: 418-428.
23. Fichorova RN (2004) Guiding the vaginal microbicide trials with biomarkers of inflammation. J Acquir Immune Defic Syndr 37 Suppl 3: S184-193.
24. Fichorova RN, Bajpai M, Chandra N, Hsiu JG, Spangler M, et al. (2004) Interleukin (IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicidal contraceptives. Biol Reprod 71: 761-769.
25. Trifonova RT, Bajpai M, Pasicznyk JM, Chandra N, Doncel GF, et al. (2007) Biomarkers of leukocyte traffic and activation in the vaginal mucosa. Biomarkers 12: 608-622.
26. Dezzutti CS, Hendrix CW, Marrazzo JM, Pan Z, Wang L, et al. (2011) Performance of swabs, lavage, and diluents to quantify biomarkers of female genital tract soluble mucosal mediators. PLoS One 6: e23136.
27. Scott ME, Wilson SS, Cosentino LA, Richardson BA, Moscicki AB, et al. (2011) Interlaboratory reproducibility of female genital tract cytokine measurements by Luminex: Implications for microbicide safety studies. Cytokine 56: 430-434.
28. Su HI, Schreiber CA, Fay C, Parry S, Elovitz MA, et al. (2011) Mucosal integrity and inflammatory markers in the female lower genital tract as potential screening tools for vaginal microbicides. Contraception 84: 525-532.
29. Lagenaur LA, Sanders-Beer BE, Brichacek B, Pal R, Liu X, et al. (2011) Prevention of vaginal SHIV transmission in macaques by a live recombinant Lactobacillus. Mucosal Immunol.
30. Yu RR, Cheng AT, Lagenaur LA, Huang W, Weiss DE, et al. (2009) A Chinese rhesus macaque (Macaca mulatta) model for vaginal Lactobacillus colonization and live microbicide development. J Med Primatol 38: 125-136.
31. Vishwanathan SA, Guenthner PC, Lin CY, Dobard C, Sharma S, et al. (2011) High susceptibility to repeated, low-dose, vaginal SHIV exposure late in the luteal phase of the menstrual cycle of pigtail macaques. J Acquir Immune Defic Syndr 57: 261-264.
32. Mirmonsef P, Gilbert D, Veazey RS, Wang J, Kendrick SR, et al. (2011) A Comparison of Lower Genital Tract Glycogen and Lactic Acid Levels in Women and Macaques: Implications for HIV and SIV Susceptibility. AIDS Res Hum Retroviruses.
33. Liu X, Lagenaur LA, Simpson DA, Essenmacher KP, Frazier-Parker CL, et al. (2006) Engineered vaginal lactobacillus strain for mucosal delivery of the human immunodeficiency virus inhibitor cyanovirin-N. Antimicrob Agents Chemother 50: 3250-3259.
34. Doyle L, Young CL, Jang SS, Hillier SL (1991) Normal vaginal aerobic and anaerobic bacterial flora of the rhesus macaque (Macaca mulatta). J Med Primatol 20: 409-413.
35. Spear GT, Gilbert D, Sikaroodi M, Doyle L, Green L, et al. (2010) Identification of rhesus macaque genital microbiota by 16S pyrosequencing shows similarities to human bacterial vaginosis: implications for use as an animal model for HIV vaginal infection. AIDS Res Hum Retroviruses 26: 193-200.
36. Gravett MG, Jin L, Pavlova SI, Tao L (2012) Lactobacillus and Pediococcus species richness and relative abundance in the vagina of rhesus monkeys (Macaca mulatta). J Med Primatol 41: 183-190.
37. Huskens D, Vermeire K, Vandemeulebroucke E, Balzarini J, Schols D (2008) Safety concerns for the potential use of cyanovirin-N as a microbicidal anti-HIV agent. Int J Biochem Cell Biol 40: 2802-2814.
38. Fichorova RN, Rheinwald JG, Anderson DJ (1997) Generation of papillomavirus-immortalized cell lines from normal human ectocervical, endocervical, and vaginal epithelium that maintain expression of tissue-specific differentiation proteins. Biol Reprod 57: 847-855.
39. Fichorova RN, Anderson DJ (1999) Differential expression of immunobiological mediators by immortalized human cervical and vaginal epithelial cells. Biol Reprod 60: 508-514.
40. Yamamoto HS, Xu Q, Fichorova RN (2013) Homeostatic properties of Lactobacillus jensenii engineered as a live vaginal anti-HIV microbicide. BMC Microbiol 13: 4.
41. Perrier S, Darakhshan F, Hajduch E (2006) IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde? FEBS Lett 580: 6289-6294.
42. Poli G, Kinter AL, Fauci AS (1994) Interleukin 1 induces expression of the human immunodeficiency virus alone and in synergy with interleukin 6 in chronically infected U1 cells: inhibition of inductive effects by the interleukin 1 receptor antagonist. Proc Natl Acad Sci U S A 91: 108-112.
43. Ghadimi D, de Vrese M, Heller KJ, Schrezenmeir J (2010) Lactic acid bacteria enhance autophagic ability of mononuclear phagocytes by increasing Th1 autophagy-promoting cytokine (IFN-gamma) and nitric oxide (NO) levels and reducing Th2 autophagy-restraining cytokines (IL-4 and IL-13) in response to Mycobacterium tuberculosis antigen. Int Immunopharmacol 10: 694-706.
44. Liu Y, Fatheree NY, Mangalat N, Rhoads JM (2010) Human-derived probiotic Lactobacillus reuteri strains differentially reduce intestinal inflammation. Am J Physiol Gastrointest Liver Physiol 299: G1087-1096.
45. Snel J, Vissers YM, Smit BA, Jongen JM, van der Meulen ET, et al. (2011) Strain-specific immunomodulatory effects of Lactobacillus plantarum strains on birch-pollen-allergic subjects out of season. Clin Exp Allergy 41: 232-242.
46. Vissers YM, Snel J, Zuurendonk PF, Kleerebezem M, Wichers HJ, et al. (2011) Lactobacillus strains differentially modulate cytokine production by hPBMC from pollen-allergic patients. FEMS Immunol Med Microbiol 61: 28-40.
47. Inamine A, Sakurai D, Horiguchi S, Yonekura S, Hanazawa T, et al. (2012) Sublingual administration of Lactobacillus paracasei KW3110 inhibits Th2-dependent allergic responses via upregulation of PD-L2 on dendritic cells. Clin Immunol 143: 170-179.